News

Get Alerts by Email

Mar 13, 2018

Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a...
- Photos 1
Mar 5, 2018

Galmed Pharmaceuticals to Report Full Year and Fourth Quarter 2017 Financial Results and Provide Business Update on Tuesday, March 13

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a...
- Photos 1
Mar 2, 2018

Galmed Pharmaceuticals to Participate in Investor Conferences in March

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmedˮ or the "Companyˮ), a clinical-stage biopharmaceutical company focused on the development of the liver-targeted SCD1 modulator Aramchol™, a...
- Photos 1
Feb 14, 2018

Galmed Announces ARRIVE Study Data

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a...
- Photos 1
Feb 8, 2018

Galmed Pharmaceuticals to Provide Corporate Update at the LEERINK Partners 7th Annual Global Healthcare Conference

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Companyˮ), a clinical-stage biopharmaceutical company focused on the development of Aramchol[TM], a once-daily, oral therapy, liver...
- Photos 1

Show per page